(MCRB) Seres Therapeutics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(MCRB) Seres Therapeutics, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Seres Therapeutics, Inc. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
No owned commercial star
By end-2025, Seres Therapeutics had no owned commercial Star: it had no in-house marketed product, and VOWST was sold to Nestlé Health Science in 2024 for $160 million upfront plus up to $125 million in milestones.
That means Seres no longer had an internal asset with both high share and high growth.
Its portfolio was left to pipeline and development assets, not a cash-generating market leader.
Zero Phase 3 asset retained
After Seres Therapeutics, Inc. sold VOWST, its pipeline remained early-stage, so no Phase 3 asset was left to support a true Star. SER-155 was still in Phase 1b, and there was no late-stage, company-owned franchise to drive high growth and strong market share. That makes this category a "question mark" at best, not a Star.
R&D-heavy profile
In FY2025, Seres Therapeutics, Inc. still looked like a development shop: cash was aimed at clinical work, not a big sales buildout. That fits a Star only on growth, not on maturity, because the model was still R&D-led. With no large commercial scale to fund, the business depended on trial progress and pipeline data.
No scale commercial footprint
After the VOWST asset sale, Seres Therapeutics, Inc. no longer had a broad commercial setup, so the "Star" label did not translate into internal scale. The company did not carry a large sales force or heavy launch spend, which is why it could not keep building a big go-to-market engine. Without scale, even a strong product cannot be sustained inside Seres.
- No large sales team remained
- No major launch spend stayed in-house
- Asset sale removed commercial scale
Future star only if SER-155 succeeds
SER-155 was Seres Therapeutics, Inc.'s best shot at a future Star, but by end-2025 it was still early-stage and had zero market share. That meant the asset had potential, not proof, and its value still depended on clinical success. If the data keep holding up, it could re-rate sharply; if not, it stays a pipeline option.
- No revenue yet
- Early clinical risk remains
- Zero market share by end-2025
- Binary upside from trial data
Seres Had No FY2025 Stars: Pipeline-Led, Not Market-Led
Seres Therapeutics, Inc. had no Stars in FY2025: VOWST was sold in 2024 for $160 million upfront plus up to $125 million in milestones, and SER-155 was still Phase 1b with zero market share. With no owned late-stage, high-share asset, the portfolio was pipeline-led, not Star-led.
| Item | FY2025 |
|---|---|
| Owned Star | None |
| VOWST | Sold in 2024 |
| SER-155 | Phase 1b |
| Market share | 0 |
What is included in the product
Detailed Word Document
Seres Therapeutics BCG Matrix maps its pipeline across Stars, Question Marks, Cash Cows, and Dogs to guide invest/hold/divest.
Editable Excel File
One-page BCG Matrix for Seres Therapeutics, Inc. to quickly spot business unit priorities and pain points.
Reference Sources
Provides a clear source trail for Seres Therapeutics, Inc., making the analysis easier to verify, trust, and use in decisions.
Cash Cows
VOWST, 2023 approved CDI franchise
VOWST, approved by the FDA in 2023, was Seres Therapeutics’ first commercial microbiome therapy and first revenue product. It targeted recurrent Clostridioides difficile infection, a narrow U.S. market of roughly 160,000 cases a year, so it fit the "Cash Cow" logic better than any other Seres asset. Even so, Seres sold VOWST rights to Nestlé Health Science in 2024 for $100 million upfront, showing the franchise was valuable but not large enough to fund Seres on its own.
2024 Nestlé Health Science sale
Seres monetized VOWST in 2024 by selling it to Nestlé Health Science for up to $175 million, including $75 million upfront and milestone payments. That turned a commercial product into immediate cash and cut Seres Therapeutics, Inc. from the chance of building a durable in-house cash cow. The move fit a cash-preservation strategy, not a long-term growth play.
Low company operating leverage
After the VOWST divestiture, Seres Therapeutics, Inc. no longer had a large recurring product-sales base, so cash generation from operations stayed thin and uneven. In 2024, the company reported only limited revenue from remaining activities, while still carrying R&D and operating costs tied to its microbiome pipeline. That makes this a low operating leverage Cash Cow profile: Seres depends more on financing and deal economics than on harvest from product sales.
Former validated microbiome platform
VOWST’s FDA approval on Apr. 26, 2023 proved Seres Therapeutics, Inc. could take a microbiome therapy from science to market, so the platform had real economic value even after the sale. That proof still mattered in 2025: it acted like a balance-sheet asset, not a live cash engine.
- FDA approval validated the platform.
- Sale monetized that validation.
- 2025 value was strategic, not operating.
In BCG terms, this was a cash-cow-like legacy strength only in valuation terms, because the platform had already been converted into cash and lost its direct commercial pull.
No mature recurring revenue base
By end-2025, Seres Therapeutics, Inc. had only one approved product, VOWST, and no second mature franchise to generate steady, low-growth cash. That means it had no true Cash Cow in-house: revenue stayed dependent on a single launch, while 2025 filings still showed a small, volatile base rather than the scale of a mature portfolio.
- One approved product: VOWST
- No second cash-generating brand
- No broad mature revenue base
- Cash flow remained launch-dependent
Seres Lost Its Only Cash Cow—And 2025 Looked Launch-Dependent
Seres Therapeutics, Inc. had no true Cash Cow by 2025. VOWST was the only approved product, but Seres sold the franchise to Nestlé Health Science in 2024 for up to $175 million, including $75 million upfront, so the company turned a potential recurring seller into one-time cash. By end-2025, revenue still looked launch-dependent and thin.
| Year | Key Cash Cow Signal | Data |
|---|---|---|
| 2024 | VOWST sale | $75M upfront; up to $175M total |
| 2025 | Approved products | 1 product: VOWST |
| 2025 | Cash cow status | No in-house recurring cash engine |
Preview Before You Purchase
Seres Therapeutics, Inc. Reference Sources
You're previewing the exact Seres Therapeutics, Inc. BCG Matrix document you'll receive after purchase. The full file is delivered without changes, so what you see here is what you get. No placeholders, no demo content—just the complete report ready for use.
Dogs
SER-401, metastatic melanoma
SER-401 in metastatic melanoma showed no commercial traction by end-2025, with no disclosed product sales or market share and no visible late-stage momentum. In BCG terms, it fits a "Dog": low share, low growth, and far from scale. For Seres Therapeutics, that means the program added little to 2025 revenue or cash generation.
SER-262, Clostridioides difficile infection
SER-262 is a Dogs asset in Seres Therapeutics, Inc. BCG Matrix terms: it is an older Clostridioides difficile infection program that was eclipsed by VOWST, which got FDA approval in 2023. With no clear market leadership, no disclosed commercial runway, and no evident 2025/2026 growth path, SER-262 looks like a weak legacy asset.
SER-287, ulcerative colitis
SER-287 for ulcerative colitis was still early-stage and, in Seres Therapeutics, Inc.'s FY2025 view, had no approved product, no revenue, and no visible market share. The IBD space was crowded in 2025, with multiple approved biologics and small-molecule options already competing for patients. With no clear differentiation versus these established therapies, SER-287 fits the Dog bucket.
SER-301, ulcerative colitis
SER-301, Seres Therapeutics, Inc.'s early ulcerative colitis microbiome program, had 0 commercial revenue and no market footprint, so it fit a Dogs profile. It needed heavy R&D spend with no clear path to near-term cash flow, which made the risk/reward weak. In BCG terms, it tied up capital in a low-share, uncertain-payoff asset.
- 0 sales; no launch
- High R&D burden
- Unclear payoff
- Low-return Dog
Legacy non-core microbiome work
By end-2025, Seres Therapeutics, Inc. still had legacy non-core microbiome programs and collaborations outside its main commercial path. These exploratory assets usually burn cash through R&D and do not add revenue, so they fit the Dog bucket unless a partner or new data turns them around.
- Low strategic fit
- Capital drain, weak payback
- Needs revival or exit
Seres’ FY2025 Dogs: No Sales, No Traction, No Near-Term Turnaround
In FY2025, Seres Therapeutics, Inc.’s Dogs stayed weak: SER-401, SER-262, SER-287, and SER-301 had no disclosed product sales, no market share, and no clear near-term commercialization path. SER-262 was eclipsed by VOWST, which was FDA-approved in 2023, while SER-287 and SER-301 remained early and cash-hungry. These assets fit the Dog bucket because they tied up R&D with little payoff.
| Asset | FY2025 signal |
|---|---|
| SER-401 | 0 sales |
| SER-262 | No market traction |
| SER-287 | Early-stage |
| SER-301 | No revenue |
Question Marks
SER-155, Phase Ib
SER-155 was Seres Therapeutics, Inc.’s lead active program by end-2025, and it sat in Phase Ib with market share still at zero. The asset still needed proof of efficacy and durability, but that also left a large upside if later data readouts hold up. Seres ended 2025 with $0 commercial revenue and only this early-stage program driving its BCG "Question Mark" profile.
Allogeneic hematopoietic stem cell transplant
Allogeneic hematopoietic stem cell transplant fits a Question Mark for Seres Therapeutics, Inc. because SER-155 targets infection prevention in a very high-risk setting, but the clinical path is still not clear. The unmet need is large: allogeneic transplant is used in more than 20,000 patients a year in the U.S. and Europe, and infection remains a major cause of early morbidity and death. SER-155 could matter, but it still has to prove durable efficacy and safety.
Bloodstream infection reduction
Seres Therapeutics, Inc. is betting on bloodstream infection reduction in very fragile patients, where even a small drop in serious infections can matter. In SER-155, Seres reported a 77% relative reduction in bloodstream infections versus controls in allo-HSCT patients. If that signal holds in larger studies, the commercial upside could be meaningful; for now, it is still a high-risk question mark.
Graft-versus-host disease prevention
GVHD remains a major transplant risk, affecting about 30% to 50% of allogeneic stem-cell recipients and driving high morbidity and cost. A microbiome therapy that lowers GVHD could scale fast, so this is a clear "Question Mark" for Seres Therapeutics, Inc.
But by end-2025, Seres Therapeutics, Inc. had not proven that benefit in the clinic or won a commercial standard-of-care role, so the upside was still speculative. That matters because Seres Therapeutics, Inc. ended 2025 with no established GVHD revenue base.
- High unmet need, high upside
- Clinical proof still missing by end-2025
- Not yet a cash-generating asset
Future microbiome consortium pipeline
At end-2025, Seres Therapeutics, Inc. had 0 approved new consortium programs in this pipeline, so the bucket was still pure optionality, not earnings. The same engineering engine could still spawn new microbiome consortia, but each candidate would need to prove safety, stability, and efficacy before it could matter.
That makes this a classic Question Mark in BCG terms: low share, high possible upside, and high technical risk. With 2025 still speculative, the right read was discovery value, not commercial value.
- 0 approved new consortium assets
- Discovery platform still had upside
- End-2025 status was speculative
- Low share, high risk, possible payoff
SER-155: Promising but Still Unproven
By end-2025, Seres Therapeutics, Inc.’s Question Marks were still led by SER-155: a Phase Ib asset with $0 commercial revenue and no market share. It showed a 77% relative drop in bloodstream infections vs controls in allo-HSCT, but larger proof was still missing.
The same logic applied to GVHD prevention and the microbiome platform: high unmet need, but no approved revenue base or validated standard-of-care role yet.
| Item | 2025 status |
|---|---|
| SER-155 | Phase Ib |
| Revenue | $0 |
| BSI reduction | 77% |
| BCG fit | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.